Patient preference does not decrease even if their usual provider is unavailable.
Telehealth has become increasingly popular since the COVID-19 pandemic and now almost three-quarters (69%) of Medicare patients are comfortable with their yearly wellness visit being conducted via telehealth, according to the results of a recent consumer survey from the virtual care network KeyChange.
The most popular benefits cited by participants were the decreased transportation time (39.25%), the option to avoid an office potentially full of sick people (30.7%) and quicker availability (20%).
The survey also found that 75% of Medicare patients would feel comfortable conducting their annual wellness visit with a provider who is not their regular physician.
"The results of this survey confirm that health systems have a tremendous opportunity to work with telehealth partners to deliver annual wellness visits to Medicare patients," said Lyle Berkowitz, M.D., CEO of KeyCare, in a press release. “A formal annual wellness visit provides great value for Medicare patients by ensuring their medical record is up to date while identifying social determinants of health issues and closing care gaps.”
These findings build upon last year’s KeyCare survey that revealed when presented with a telehealth option, only 37% of patients prefer going into the office.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More